ClinicalTrials.gg
RecruitingNCT06165328CTOCOCRECUpdated Feb 29, 2024

The Comparison Between Computed Tomography and Colonoscope in Detecting Colorectal Tumors in Patients With FIT+

An observational study in Patients at Risk of Colorectal Cancer, sponsored by Hat Yai Medical Education Center. Recruiting at 1 site in Thailand. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Hat Yai Medical Education Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
241
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Colorectal Neoplasms with a site in Thailand — 3 open to participants now, 7 under way, 4 of them phase 3. Colorectal Neoplasms · Thailand.

Started
2024
with 2 others
Observational
2 of 22
1 open now
Registered
19th of 22
by date
Lead sponsor
1 of 22
Hat Yai Medical Education Center

Among the 22 studies in Colorectal Neoplasms with a site in Thailand, this one is one of 3 that started in 2024, is one of 2 observational ones, and was the 19th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 22 studies in Colorectal Neoplasms with a site in Thailand are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colorectal Neoplasms with a site in Thailand, or all of them as a file.
02

Study summary

Colonoscopy is the mainstay modality of choice in colorectal cancer screening worldwide. However, the rate of colonoscopy for colorectal cancer screening is very low (approximately 5-10%) because of the limited local medical resources (such as endoscopists and regional endoscope). This observational diagnostic test study aims to compare the diagnostic yield of routine computed tomography and colonoscopy in detecting colorectal tumors in patients at risk of colorectal cancer (aged more than 50 years and FIT+). The main question[s] it aims to answer are:

  1. To compare the diagnostic yield between the routine computed tomography and colonoscopy.
  2. To compare the procedure-related adverse events between the routine computed tomography and colonoscopy.
Read the detailed description

All enrolled patients underwent routine CT scans of whole abdomen, then subsequently under went a colonoscopy on the next day

03

Conditions studied

  • Patients at Risk of Colorectal Cancer

Keywords

  • colorectal tumor
  • colorectal cancer
  • CT scan
  • colonoscopy
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients aged 50-70 years old who underwent FIT test for an indication of colorectal cancer screening as National program of Thailand.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fit test +
  2. Normal count and normal result of PT,

Exclusion criteria

Exclusion Criteria:

  1. pregnancy or lactation
  2. uncontrolled Diabetes Mellitus, hypertension, asthma, congestive heart failure
  3. recent coronary artery disease within 3 months
  4. lesser than 30 mL/min/1.73m2
  5. hemophilia or uncontrolled or uncorrected coagulopathy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
241 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cohort1

    Patients with aged more than 50 years and had FIT test +

    Diagnostic Test: CT and colonoscopy

Interventions

  • Diagnostic testCT and colonoscopy

    All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.

06

What researchers measure

Primary outcomes

  1. Diagnostic yield in diagnosis colorectal tumor

    Sensitivity, specitivity, accuracy

    Time frame: 2 weeks

Secondary outcomes

  1. Procedure-related adverse events

    Procedure-related adverse events such as, contrast induced nephropathy, contrast allergy, colonoscope-related perforation, post polypectomy bleeding

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531. doi: 10.1038/s41575-022-00612-y. Epub 2022 May 3. Erratum In: Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):551. doi: 10.1038/s41575-022-00661-3. PubMed 35505243 ↗
  • Wong MCS, Chan FKL. Colorectal cancer screening in middle eastern countries: Current status and future strategies to enhance screening. Saudi J Gastroenterol. 2019 Jan-Feb;25(1):1-2. doi: 10.4103/sjg.SJG_611_18. No abstract available. PubMed 30665995 ↗
  • Tanaka H, Oka S, Shiotani A, Sugimoto M, Suzuki H, Naito Y, Handa O, Hisamatsu T, Fukudo S, Fujishiro M, Motoya S, Yahagi N, Yamaguchi S, Chan FKL, Lee SY, Li B, Ang TL, Abdullah M, Tablante MC, Prachayakul V, Tanaka S; International Gastrointestinal Consensus Symposium Study Group. Current Status of Diagnosis and Treatment of Colorectal Cancer in Asian Countries: A Questionnaire Survey. Digestion. 2024;105(1):62-68. doi: 10.1159/000531706. Epub 2023 Jul 27. PubMed 37497916 ↗
  • Ganeshan A, Upponi S, Uberoi R, D'Costa H, Picking C, Bungay H. Minimal-preparation CT colon in detection of colonic cancer, the Oxford experience. Age Ageing. 2007 Jan;36(1):48-52. doi: 10.1093/ageing/afl116. Epub 2006 Nov 17. PubMed 17114203 ↗
  • Pilleul F, Bansac-Lamblin A, Monneuse O, Dumortier J, Milot L, Valette PJ. Water enema computed tomography: diagnostic tool in suspicion of colorectal tumor. Gastroenterol Clin Biol. 2006 Feb;30(2):231-4. doi: 10.1016/s0399-8320(06)73158-x. PubMed 16565655 ↗
  • Miller J, Maeda Y, Au S, Gunn F, Porteous L, Pattenden R, MacLean P, Noble CL, Glancy S, Dunlop MG, Din FVN. Short-term outcomes of a COVID-adapted triage pathway for colorectal cancer detection. Colorectal Dis. 2021 Jul;23(7):1639-1648. doi: 10.1111/codi.15618. Epub 2021 Mar 29. PubMed 33682302 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 10 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2023
First posted
Dec 11, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Nov 1, 2024
CompletionEst.
Dec 31, 2024
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06165328
Lead sponsor
Hat Yai Medical Education Center
Collaborators
HatYai Hospital
Responsible party
Arunchai Chang (Head of Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Hat Yai Medical Education Center) — Principal investigator
First posted
Dec 11, 2023
Start date
Jan 1, 2024
Primary completion
Nov 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Feb 29, 2024

Study contacts

Arunchai Chang, MD
Contact
busmdcu58@gmail.com
+66650979414
Araya Kaimook, MD
Contact
araya@cpird.in.th
+66815424454
Arunchai Chang, MD
principal investigator · Division of Gastroenetrology, Department of Internal Medicine, Hatyai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion